Drugs / OXi4503
OXi4503
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01085656 | Feb 2011 → Jan 2016 | acute myeloid leukemia, myelodysplastic syndrome | University of Florida | Terminated | No outcome recorded |
| Phase 1 | NCT00977210 | Jul 2005 → Sep 2010 | cancer | Mateon Therapeutics | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02576301 | Oct 2015 → Oct 2019 | acute myeloid leukemia, myelodysplastic syndrome | Mateon Therapeutics | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OXi4503 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02576301 ↗ |
| Known as | CA1P | “Preclinical studies show that OXi4503 (combretastatin A1 diphosphate, CA1P) is more potent than other clinically evaluated vascular-disrupting agents.” PMID 22235096 ↗ Jan 2012 |
| Known as | combretastatin A1 diphosphate | “Preclinical studies show that OXi4503 (combretastatin A1 diphosphate, CA1P) is more potent than other clinically evaluated vascular-disrupting agents.” PMID 22235096 ↗ Jan 2012 |
| Modality | Other / unclassified | “OXi4503 is a novel microtubule targeting agent” NCT01085656 ↗ |
| Route | Intravenous | “given as an intravenous infusion” NCT00977210 ↗ |